Royal Bank Of Canada started coverage on shares of ObsEva SA (NASDAQ:OBSV) in a report issued on Thursday morning, MarketBeat Ratings reports. The firm issued an outperform rating and a $22.00 price objective on the stock.
Other analysts have also issued research reports about the stock. HC Wainwright set a $27.00 target price on shares of ObsEva SA and gave the company a buy rating in a research report on Wednesday, August 16th. Leerink Swann reiterated an outperform rating and issued a $18.00 target price on shares of ObsEva SA in a research report on Wednesday, August 16th. Finally, Zacks Investment Research upgraded shares of ObsEva SA from a sell rating to a hold rating in a research report on Wednesday, July 19th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. ObsEva SA currently has an average rating of Buy and a consensus target price of $23.00.
Shares of ObsEva SA (OBSV) opened at 6.95 on Thursday. ObsEva SA has a 52 week low of $6.77 and a 52 week high of $14.18. The stock’s market cap is $198.05 million. The firm has a 50-day moving average of $6.96 and a 200 day moving average of $9.67.
ObsEva SA (NASDAQ:OBSV) last announced its earnings results on Tuesday, August 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.13). During the same quarter last year, the business posted ($0.30) EPS. On average, equities analysts forecast that ObsEva SA will post ($2.38) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://ledgergazette.com/2017/09/17/royal-bank-of-canada-begins-coverage-on-obseva-sa-obsv.html.
Large investors have recently bought and sold shares of the company. Baker Avenue Asset Management LP purchased a new position in shares of ObsEva SA in the first quarter worth about $104,000. Paloma Partners Management Co purchased a new position in shares of ObsEva SA in the first quarter worth about $131,000. Iguana Healthcare Management LLC purchased a new position in shares of ObsEva SA in the first quarter worth about $260,000. Spark Investment Management LLC purchased a new position in shares of ObsEva SA in the first quarter worth about $518,000. Finally, Nexthera Capital LP purchased a new position in shares of ObsEva SA in the first quarter worth about $521,000. 48.46% of the stock is currently owned by hedge funds and other institutional investors.
ObsEva SA Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.